That raises an uncomfortable but increasingly important question: Are we still underestimating PJI by continuing to frame it mainly as a surgical complication?

The comparison many clinicians may find provocative

In orthopedics, complications are typically understood as discrete events: identify the problem, intervene, resolve it, and move on. PJI does not always follow that script.

The available evidence points to a condition that can be persistent, recurrent, systemically consequential, and closely tied to long-term survival: a pattern more familiar to oncologists than to surgeons managing a postoperative complication. A growing body of literature suggests that thinking about PJI through that lens, not because it is biologically equivalent to malignant disease, but because its consequences can begin to resemble it, may be overdue.

The comparison is provocative for a reason. But it is increasingly difficult to ignore.

The five-year mortality rate for PJI following Total Hip Arthroplasty (THA) is approximately ~ 15-16%¹. That places the mortality burden in the same range as some common cancers, including breast cancer, and higher than the figures cited there for prostate cancer or melanoma.

Even when different cohorts are examined, the message remains difficult to ignore: patients who develop PJI appear to face a materially worse long-term prognosis than patients undergoing uncomplicated arthroplasty.

Why mortality changes the conversation

In clinical practice, PJI is often discussed through the lens of revision strategy, organism profile, implant retention, and antibiotic planning. All of that matters.

But mortality data changes the tone of the discussion.

Once a condition is associated with a meaningful long-term risk of death, it becomes harder to describe it as simply a technical failure of surgery. It starts to demand a different level of seriousness in how we counsel patients, how we select treatment pathways, and how we organise follow-up.

This may be where the oncology analogy is most useful. The value of the comparison is not rhetorical. It is practical.

Oncology has long treated survival, recurrence, treatment burden, and multidisciplinary decision-making as inseparable parts of care. PJI may warrant more of that same mindset.

The treatment can be as consequential as the disease

Another important point to raise is that outcomes are shaped not only by the presence of infection, but also by the demands of treatment.

Two-stage exchange remains one of the most definitive approaches in many PJI scenarios. Yet data suggests that five-year mortality for patients undergoing two-stage exchange can be as high as 11.5%.,

That does not mean the procedure is inappropriate. It means the burden of treatment itself cannot be viewed in isolation from the burden of disease.

Major repeat surgery, reduced mobility, prolonged recovery, and extended antibiotic exposure all carry consequences. In other fields of medicine, clinicians are accustomed to weighing therapeutic intensity against patient reserve and likely benefit. In PJI, that balance may deserve more explicit attention than it often receives.

Recurrence remains one of the central problems

If mortality is one reason the oncology comparison resonates, recurrence is another. Eradication rates of roughly 65% to 85%, imply failure or reinfection rates of 15% to 35%.,Those are not trivial margins. They suggest that for a meaningful proportion of patients, PJI is not a one-time event with a clean endpoint.

This is where the conventional language of “complication management” may fall short. Complications are usually expected to resolve. Chronic disease states require surveillance, longitudinal planning, and continued risk assessment.

That distinction matters because it shapes clinician behavior. It influences how strongly teams monitor patients over time, how expectations are set with families, and how seriously the possibility of recurrence is integrated into care planning.

What this reframing could change in practice

Viewing PJI as a severe systemic disease rather than only a local surgical problem does not solve the problem. But it could sharpen clinical decision-making in several ways:

• Patient counselling may become more realistic.

  Discussions can move beyond infection control alone and include survival, recurrence, and treatment burden.

• Multidisciplinary management may become more central.

  Infectious disease, surgery, rehabilitation, and medical optimisation may need to be integrated earlier and more deliberately.

• Long-term follow-up may deserve greater emphasis.

  If recurrence risk remains substantial, discharge from acute treatment should not be mistaken for resolution of the wider problem.

• Research priorities may shift.

  Success may need to be measured not only by short-term eradication, but by survivorship, function, and durable recovery.

The harder question for the field

There is, of course, a risk in strong analogies. If overused, they can oversimplify. PJI is not cancer. The underlying biology is different, the treatment paradigms are different, and the patient experience is different.

Still, the comparison may be valuable precisely because it unsettles a familiar assumption.

If a condition carries substantial mortality, demands aggressive treatment, and recurs often enough to alter long-term prognosis, should the field continue to talk about it as though it were simply one complication among many?

That may be the more important issue here. Not terminology for its own sake, but whether our language is still aligned with the true clinical burden.

What do you think: does orthopedics need a more oncology-like framework for discussing and managing PJI or does that comparison risk obscuring more than it clarifies?